Impaired Antibody Response to the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis
Objective With a vaccine effectiveness of 95% for preventing coronavirus disease 2019 (COVID‐19), Pfizer‐BioNTech BNT162b2 (BNT162b2) was the first vaccine against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) to be approved. However, immunosuppressive therapy was an exclusion criteri...
Main Authors: | Christian Ammitzbøll, Lars Erik Bartels, Jakob Bøgh Andersen, Signe Risbøl Vils, Clara Elbæk Mistegård, Anders Dahl Johannsen, Marie‐Louise From Hermansen, Marianne Kragh Thomsen, Christian Erikstrup, Ellen‐Margrethe Hauge, Anne Troldborg |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-09-01
|
Series: | ACR Open Rheumatology |
Online Access: | https://doi.org/10.1002/acr2.11299 |
Similar Items
-
Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
by: Xin Rong Lim, et al.
Published: (2021-08-01) -
Acute myocarditis following administration of BNT162b2 vaccine
by: Mhd Baraa Habib, et al.
Published: (2021-01-01) -
Case of de novo nail psoriasis triggered by the second dose of Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine
by: Jose W. Ricardo, MD, et al.
Published: (2021-11-01) -
Supraclavicular lymphadenopathy secondary to COVID-19 BNT162b2 vaccine
by: B Roca, et al.
Published: (2021-01-01) -
Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany
by: Tatjana Schwarz, et al.
Published: (2021-08-01)